PubMed Health⌕ Search

Biomedical subjects

Jian-rong Huang

Publications and source records attributed to Jian-rong Huang.

5 recordsLinked to original sources
PubMed2004

[Stimulation of insulin-like growth factor-I to chondrogenesis of engineering cartilage tissue].

OBJECTIVE: To explore the ability of insulin-like growth factor-I (IGF-I) and hyaluracan acid in prompting chondrogenesis of engineering cartilage tissue. METHODS: Human articular chondrocytes were isolated and cultured in DMEM plus 10% fetal bovine serum. They were divided into three groups: hyaluracan acid + chondrocytes + IGF-I group (IGF-I group), hyaluracan acid + chondrocytes group (cell group), hyaluracan acid group (control group). The ability of chondrogenesis was investigated by HE and toluidine blue staining, human collagen II immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR). RESULTS: Both cell group and IGF-I group could develop into cartilage tissue in the sixth week while control group could not. The number of cartilage lacuna in IGF-I group were more than that in cell group. Human collagen II immunohistochemistry showed that there were stronger positive cell in IGF-I group than in cell group, collagen II mRNA expression was more higher and collagen I mRNA expression was lower in IGF-I group than in cell group. CONCLUSION: Insulin growth factor-I can prompt chondrogenesis of engineering cartilage tissue and ameliorate the quality of engineering cartilage tissue in vitro.

Cartilage, Articular↗
PubMed2003

[Study of severe hepatitis treated with a hybrid artificial liver support system].

OBJECTIVES: To evaluate the efficacy of a hybrid artificial liver support system in the treatment of chronic severe hepatitis. METHODS: The hybrid artificial liver support system (HALSS) consisted of a bioreactor containing more than 5 x 10(9) porcine hepatocytes and plasma exchange device. 15 patients with chronic severe viral hepatitis were treated with the hybrid system. RESULTS: All the patients experienced a reduction in symptoms, such as fatigue, abdominal distention or ascites. After each treatment serum total bilirubin decreased markedly (from 493.5 micromol/L+-139.8 micromol/L to 250.9 micromol/L+-91.3 micromol/L, t=8.695, P<0.001), while prothrombin activity increased (from 24.5%+-8.4% to 30.6%+-6.3%, t=3.325, P<0.01). There were 11 patients whose progress of hepatocytes necrosis stopped after HALSS treatment, and finally they recovered completely. Four patients died of their worsen conditions. No serious adverse events were noted in the 15 patients. CONCLUSION: HALSS is a reliable hepatic support device for chronic severe hepatitis.

Adult↗